Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to reflect a new version of the HHS Vulnerability Disclosure, changing from v2.16.6 to v2.16.8.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page now includes a service alert regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours. Additionally, the section indicating 'No Results Posted' has been removed.SummaryDifference0.8%
- Check26 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference0.9%
- Check34 days agoNo Change Detected
- Check41 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check48 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.